JP Morgan Chase
CTKB icon

JP Morgan Chase’s Cytek Biosciences CTKB Stock Holding History

JP Morgan Chase’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$616K Sell
141,864
-157,226
-53% -$671K ﹤0.01% 4962
2026
Q1 		$1.29M Sell
299,090
-29,763
-9% -$141K ﹤0.01% 4433
2025
Q4 		$1.66M Sell
328,853
-29,870
-8% -$139K ﹤0.01% 4233
2025
Q3 		$1.24M Sell
358,723
-71,385
-17% -$268K ﹤0.01% 4428
2025
Q2 		$1.46M Sell
430,108
-241,205
-36% -$804K ﹤0.01% 4137
2025
Q1 		$2.69M Sell
671,313
-276,370
-29% -$1.43M ﹤0.01% 3650
2024
Q4 		$6.15M Buy
947,683
+349,146
+58% +$2.08M ﹤0.01% 3170
2024
Q3 		$3.32M Sell
598,537
-9,903
-2% -$56.2K ﹤0.01% 3547
2024
Q2 		$3.4M Buy
608,440
+523,028
+612% +$3.14M ﹤0.01% 3345
2024
Q1 		$573K Sell
85,412
-62,184
-42% -$492K ﹤0.01% 4713
2023
Q4 		$1.35M Buy
147,596
+9,397
+7% +$59.1K ﹤0.01% 4130
2023
Q3 		$763K Sell
138,199
-6,291
-4% -$50.5K ﹤0.01% 4250
2023
Q2 		$1.23M Buy
144,490
+54,801
+61% +$492K ﹤0.01% 3890
2023
Q1 		$824K Buy
89,689
+21,414
+31% +$230K ﹤0.01% 4179
2022
Q4 		$697K Buy
68,275
+4,984
+8% +$67K ﹤0.01% 4298
2022
Q3 		$931K Buy
63,291
+1,837
+3% +$23.9K ﹤0.01% 4058
2022
Q2 		$659K Buy
61,454
+11,548
+23% +$115K ﹤0.01% 4384
2022
Q1 		$538K Buy
49,906
+39,974
+402% +$540K ﹤0.01% 4661
2021
Q4 		$162K Sell
9,932
-3,004
-23% -$62.9K ﹤0.01% 5467
2021
Q3 		$277K Buy
+12,936
New +$304K ﹤0.01% 5059

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's CTKB Position: Q2 2026 in Review

JP Morgan Chase reduced its Cytek Biosciences (CTKB) stake by 53% in Q2 2026, selling an estimated $671K and leaving 141,864 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #4962.

JP Morgan Chase first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $6.15M in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • JP Morgan Chase held 141,864 shares of Cytek Biosciences worth $616K as of Q2 2026.
  • JP Morgan Chase sold 157,226 Cytek Biosciences shares in Q2 2026, an estimated $671K.
  • Cytek Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4962 holding.
  • JP Morgan Chase first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Cytek Biosciences position peaked at $6.15M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.